Global Antidepressant Drugs Market to expand with 3.12% CAGR through 2023

November 29, 2019


According to the research report titled ‘Global Antidepressant Drugs Market: Analysis by Drugs Class, By Sales Channel, By Region, By Country: Opportunities and Forecasts (2018-2023) - By Region (APAC, N. America, Europe, RoW), By Country (US, Canada, UK, Germany, China, India, Japan, Brazil, South Arabia)’ available with Market Study Report LLC, the global antidepressant drugs market is estimated to grow with a CAGR of 3.12% during the period of 2018-2023.
 

Rising working population along with shifting trend of hectic lifestyle, and growing occurrences of depression among the population, especially in millennials, are the major factors driving the growth of antidepressant drugs market for the forecast period.
 

As per drugs class, antidepressant drugs market is categorized into tricyclic antidepressants, selective norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, benzodiazepines, monoamine oxidase inhibitors, novel agents, and antipsychotics. According to the report, selective serotonin reuptake inhibitors (SSRIs) segment dominated the market in 2018 and is presumed to register constant growth over the analysis period, due to growing concerns on mental disorders, increasing per capita income, and mounting expenditures on healthcare. 
 

In terms of sales channel, the industry is classified into retail pharmacies, hospitals & clinics, and others. While considering the geographical landscape, the global antidepressant drugs market is divided into regions namely, Europe, North America, Asia-Pacific, and rest of the world, with key focus on countries such as Canada, US, UK, Germany, Japan, India, China, Saudi Arabia, and Brazil.
 

The report cites that North America antidepressant drugs market held the largest regional share in 2018, owing to rising healthcare spending, development of new products, increasing average spending power, coupled with growing number of clinics and hospitals in the region.
 

Request sample copy of this Reporthttps://www.marketstudyreport.com/request-a-sample/1227757/
 

The key players in global antidepressant drugs market are GlaxoSmithKline, Pfizer, Forest Laboratories, Allergan, Novartis, Takeda, and Eli Lilly.
 

The research report on antidepressant drugs market is analyzes the competitive landscape using Porter’s Five Force analysis and SWOT analysis. It encompasses details about the regulatory landscape influencing the market. In-depth comprehension regarding market dynamics and prevailing trends is outlined in the study.


Frequently Asked Questions (FAQ) :

Rising working population along with shifting trend of hectic lifestyle, and growing occurrences of depression among the population, especially in millennials, are the major factors driving the growth of antidepressant drugs market for the forecast period.
As per drugs class, antidepressant drugs market is categorized into tricyclic antidepressants, selective norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, benzodiazepines, monoamine oxidase inhibitors, novel agents, and antipsychotics. According to the report, selective serotonin reuptake inhibitors (SSRIs) segment dominated the market in 2018 and is presumed to register constant growth over the analysis period, due to growing concerns on mental disorders, increasing per capita income, and mounting expenditures on healthcare.
North America antidepressant drugs market held the largest regional share in 2018 owing to rising healthcare spending, development of new products, increasing average spending power coupled with growing number of clinics and hospitals in the region.
The key players in global antidepressant drugs market are GlaxoSmithKline, Pfizer, Forest Laboratories, Allergan, Novartis, Takeda, and Eli Lilly.